{
  "attach_pages": "5",
  "attach_size": "853",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP201706120642483775_1.pdf?1497298682000.pdf",
  "company_code": "80000038",
  "eitime": "2017-06-12 20:18:42",
  "extend": {},
  "info_code": "AP201706120642483775",
  "language": "0",
  "notice_date": "2017-06-12 00:00:00",
  "notice_title": "受让利拉鲁肽和地西他滨，丰富产品线布局",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "publish_relation": {
    "originalCode": "465",
    "publishName": "化学制药"
  },
  "rating": "BB",
  "researcher": "吴汉靓,蔡明子",
  "security": [
    {
      "market_uni": "0",
      "publish_relation": [
        {
          "originalCode": "465",
          "publishName": "化学制药"
        }
      ],
      "short_name": "华东医药",
      "short_name_ch": "华东医药",
      "short_name_cht": "華東醫藥",
      "short_name_en": "HD MEDICINE",
      "stock": "000963"
    }
  ],
  "short_name": "华东医药",
  "source_sample_name": "民生证券",
  "star": "3"
}